Tag
This study reveals that many patients with primary aldosteronism have inappropriately normal aldosterone levels and shows that modifying the aldosterone-to-renin ratio improves sensitivity in diagnosis without compromising specificity.
This article evaluates strategies for interpreting consecutive aldosterone-to-renin ratio tests in primary aldosteronism diagnosis, highlighting the diagnostic trade-offs and guiding clinical decision-making based on discordant or concordan
This article examines the debate on whether RAAS-modifying antihypertensives should be stopped before testing for primary aldosteronism, weighing diagnostic accuracy against patient safety and feasibility.
This study demonstrates that urinary aldosterone measurement by LC-MS/MS outperforms immunoassay in diagnosing primary aldosteronism, especially when urinary sodium is within an optimal range, offering improved sensitivity and specificity f
This review synthesizes evidence linking the 2025 Primary Aldosteronism Severity Classification (PASC) with adrenal venous sampling (AVS) lateralization and treatment outcomes, highlighting its potential to enhance precision in PA managemen
68Ga-pentixafor PET/CT parameters correlate with clinical success post-adrenalectomy in primary aldosteronism, offering prognostic insights linked to histopathologic subtypes and CXCR4 expression.
This article synthesizes evidence from a 2026 Danish nationwide cohort and supporting literature, illustrating that renin-independent aldosterone production represents a continuous risk gradient for kidney failure and MACE, even below tradi
Recent data from the ARIC study and emerging expert consensus are redefining primary aldosteronism. Rather than a rare, all-or-nothing condition, it is now viewed as a broad spectrum where even subclinical elevations significantly increase
Researchers have discovered that measuring oxygen partial pressure (pO2) can significantly improve the accuracy and speed of Adrenal Venous Sampling, providing a cost-effective tool for diagnosing Primary Aldosteronism.
A 2025 systematic review and meta-analysis found that patients with primary aldosteronism whose renin rose after mineralocorticoid receptor antagonist therapy had substantially lower cardiovascular event rates and possibly lower mortality,
Emerging evidence links subclinical primary aldosteronism to significantly increased cardiovascular risk, even in normotensive individuals, highlighting the need for refined screening and personalized hypertension management.
